Issue link: http://read.uberflip.com/i/1513142
New drug revolutionizes treatment of cystic fibrosis. Canadians with cystic fibrosis (CF) are literally breathing easier—and living longer—thanks to a single new drug, Trikafta. Launched in 2021 in Canada, it acts upon the genetic mutations that cause CF rather than just treating symptoms. What truly sets it apart is its potential to treat up to 90% of patients, including children, whereas previous medications in the drug class are indicated for much smaller patient populations. Claims data help tell the story of Trikafta's dramatic impact on both patients and drug plans. For 2022, TELUS Health's book of business recorded 905 claimants for CF drugs, more than double the number five years ago (395 in 2018). The total eligible amount in 2022 was $122.9 million, more than quadruple the $28.2 million reported for 2018. Trikafta accounted for 50.1% of claimants and 80.3% of the eligible amount in 2022. Stepping back, claimants for CF drugs represented just 0.012% of all claimants in 2022 (chart 21). When spread out across all insured individuals, their number is even more negligible, at just 0.007%. Similarly, CF drugs accounted for just 0.022% of all claims in 2022 (chart 22). Nonetheless, these numbers have steadily grown over the past five years following the introduction of a new class of medications, called modulators, including Trikafta. Prior treatment options were approved for specific genetic mutations associated with CF whereas Trikafta has been approved with a much broader indication. Trikafta also received an expanded indication for children in 2022 and is now approved for children as young as six years old, says Lee. P. 20